Review Article

The Emerging Role of Senescence in Ocular Disease

Parameswaran G. Sreekumar,1 David R. Hinton,2,3 and Ram Kannan1,4

1The Stephen J. Ryan Initiative for Macular Research (RIMR), Doheny Eye Institute, Los Angeles, CA 90033, USA
2Department of Pathology, Keck School of Medicine of the University of Southern California, Los Angeles, CA 90033, USA
3Department Ophthalmology, USC Roski Eye Institute, Keck School of Medicine of the University of Southern California, Los Angeles, CA 90033, USA
4Stein Eye Institute, Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA

Correspondence should be addressed to Ram Kannan; rkannan@doheny.org

Received 18 December 2019; Accepted 14 February 2020; Published 9 March 2020

Guest Editor: Pamela M. Martin

Copyright © 2020 Parameswaran G. Sreekumar et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Cellular senescence is a state of irreversible cell cycle arrest in response to an array of cellular stresses. An important role for senescence has been shown for a number of pathophysiological conditions that include cardiovascular disease, pulmonary fibrosis, and diseases of the skin. However, whether senescence contributes to the progression of age-related macular degeneration (AMD) has not been studied in detail so far and the present review describes the recent research on this topic. We present an overview of the types of senescence, pathways of senescence, senescence-associated secretory phenotype (SASP), the role of mitochondria, and their functional implications along with antisenescent therapies. As a central mechanism, senescent cells can impact the surrounding tissue microenvironment via the secretion of a pool of bioactive molecules, termed the SASP. An updated summary of a number of new members of the ever-growing SASP family is presented. Further, we introduce the significance of mechanisms by which mitochondria may participate in the development of cellular senescence. Emerging evidence shows that extracellular vesicles (EVs) are important mediators of the effects of senescent cells on their microenvironment. Based on recent studies, there is reasonable evidence that senescence could be a modifiable factor, and hence, it may be possible to delay age-related diseases by modulating basic aging mechanisms using SASP inhibitors/senolytic drugs. Thus, antisenescent therapies in aging and age-related diseases appear to have a promising potential.

1. Introduction

Cellular senescence is the irreversible loss of proliferation potential of somatic cells and a variety of associated phenotypic changes that follow [1]. The concept of cellular senescence stems from pioneering studies showing that human diploid fibroblasts have a finite proliferative capacity in culture, despite the fact that they can stay metabolically active even after entering a stable, nondividing stage [2]. Subsequently, it was shown that senescence could be induced prematurely by many agents. Several independent studies have shown that senescent cells also play a role in multiple biological processes such as embryonic development, wound healing, tissue repair, tumorigenesis, aging, and age-related disease [3]. Thus, studying senescence in the eye and its association with age-related macular degeneration (AMD) will be of great interest. Herein, the nature and role of multiple senescence inducers characterized by an array of multiple biomarkers in use as well as mechanisms of cellular senescence are reviewed. In addition, the role of mitochondria in cellular senescence with special reference to ocular diseases such as AMD is also addressed. Finally, the review summarizes available information on senolytic drugs currently used in animal models and in clinical trials.

2. Acute or Chronic Senescence

Given the involvement of the process of senescence in many activities, it raises the question whether processes of the senescent cells involved could be similar or different. Generally, senescence belongs to one of two categories: acute (transient or programmed) or chronic (damage/stress induced) [4, 5].
Such differentiation would allow understanding the dual (beneficial vs. harmful) role of senescence on normal development and regenerative processes, as well as its role in human disease and aging. Developmentally programmed senescence is a normal physiological process of the body that occurs in response to developmental events, whereas damage-/stress-induced senescence is triggered by nonphysiological stimuli or disease stages.

Acute senescence is mostly beneficial and presumably does not contribute to aging; it relies on the coordinated action of senescent cell production and subsequent elimination—the processes involved in wound healing, tissue remodeling, and embryogenesis. Senescence has been demonstrated in the endolymphatic sac and mesonephros of the mouse and human embryos followed by macrophage-mediated removal of senescence cells [4]. Further evidence of senescence was shown in the apical ectodermal ridge and the senescence-associated secretory phenotype (SASP) produced by these cells induces tissue remodeling [6]. Developmental senescence is p21 dependent, but p53 independent, and shares many common features with stress-induced senescence, including a common gene expression signature and senescence-associated \( \beta \)-galactosidase activity [4]. These landmark studies revealed that cellular senescence during embryonic development is a programmed, transient event that contributes to tissue remodeling via SASP or to altered cellularity through paracrine effects of developmental versus pathological senescence on normal physiology. Paradoxically, while chronic senescence can initially have beneficial effects, its long-term existence could potentially aggravate age-related diseases [7]. “Chronic” senescence develops gradually because of progressive damage over time as seen in aging and age-related diseases. During chronic senescence, the switch from temporal to persistent cell cycle arrest appears to be random, induced by the multiple inducing factors acting simultaneously on a cell. These results in arrest of proliferation and ultimately cells become dysfunctional and most importantly negatively affect local environment by a nonautonomous mechanism [8]. The differential effects of developmental versus pathological senescence on aging could be associated with their effect on other cells via the SASP. Therefore, removal of chronic senescent cells during both premature and normal aging is able to reduce the development and progression of many age-associated dysfunctions [9, 10]. However, the molecular mechanism governing the different types of senescence in vitro and in vivo is still not fully explored. It is hypothesized that the kinetics and efficiency of senescent cell clearance could be one of the key differences between acute and chronic senescence. Further research will strengthen our understanding of the relationship between acute vs. chronic senescence.

3. The Beneficial and Detrimental Role of Senescent Cells

As described earlier, senescence has been shown to have a dual role, beneficial in some contexts and detrimental in others. Senescence acts by tumor suppressor mechanisms and thus inhibits the proliferation of cancer cells and is involved in embryonic development [4, 6], wound healing [11], and tissue repair [12, 13]. Senescent cells are metabolically highly active and actively secrete an array of proinflammatory cytokines and chemokines, growth factors and extracellular matrix degrading proteins, and the SASPs [14]. It is believed that SASP molecules stimulate movement of immune cells to the senescent cells; activate and promote their clearance [12].

The beneficial process of the senescence can be compromised in aged tissues, resulting in the accumulation of senescent cells that could potentially enhance tissue dysfunction through SASP which is particularly rich in proinflammatory cytokines and matrix metalloproteinases [15–19]. Thus, senescence has been linked to aging and age-related diseases. For example, aging human skin has increased numbers of cells that are positive for SA-\( \beta \)-gal [20]. In aged cells, the components of SASP has been shown to activate neighboring healthy cells to senescent cells [21]. It is of utmost interest to learn why these senescent cells in aging are not eliminated as is the case for embryonic cells and the inefficient immune system may play a role in this regard.

4. The Phenotype Associated with Cellular Senescence

Senescent cells are featured by an array of specialized features which have been extensively reviewed [3, 22, 23]. Since senescent cells are widely heterogeneous and some of their features are common in other nonsenescence cellular states, it is difficult to clearly identify senescent cells using a few markers [22, 24]. The following are some of the phenotypes associated with senescent cells:

(i) Senescence is generally accompanied by significant morphological alterations. The senescent cells become flat and enlarged more than double the size of nonsenescence cells due to rearrangement of the cytoskeleton, particularly vimentin filaments [25, 26]

(ii) Senescence-associated heterochromatin foci (SAHF) are specialized domains of facultative heterochromatin observed in the nuclei of senescent cells as punctate DNA-stained dense foci [27]. Specifically, SAHF are not associated with nonsenescence or quiescent state

(iii) Senescent cells normally display increased activity of the acidic senescence-associated \( \beta \)-galactosidase (SA-\( \beta \)-gal), which partly reflects the increase in lysosomal mass [20, 28]

(iv) Most senescent cells are characterized by the increased expression of antiproliferative molecules (p16INK4a). Increased expression of p16INK4a with age in mice and humans has been well documented [29–31]

(v) Senescent cells secrete cytokines, chemokines, extracellular matrix proteases, and growth factors, collectively known as SASP or senescence-messaging secretome [32, 33]
Senescent cells are characterized by significant changes in mitochondrial morphology, function, and metabolism. Senescent cells remain metabolically active and have increased mitochondrial biogenesis and respiration [34].

5. Biomarkers of Senescence

As described above, no single characteristic is exclusive to the senescent state. Nor do all senescent cells display all the senescence markers identified so far. The identification of senescent cells in vivo is challenging, especially considering their diversity and heterogeneity. Therefore, senescent cells are generally identified by an array of characteristics. Though an array of senescence markers has been proposed and widely used in multiple cell types, no single one can reliably identify senescent cells either in vitro or in vivo. The most widely used markers of senescence include the senescence-associated β-galactosidase (SA-β-gal) reactivity [15, 20, 35–39], increased expression of the cyclin-dependent kinase (CDK) inhibitor p16INK4a [15, 30, 36–40], p21 (CIP1/WAF1) [36–39, 41, 42], p53 [36, 37, 41, 42], induction of SASP factors [14, 41, 43–50], mitochondrial DNA modifications [39, 50–57], and chromatin modifications [37, 47, 58, 59] (Figure 1). The limitation is that even a combination of multiple markers does not truly represent senescence but could also describe long-term cell arrest. That is one of the major reasons for intensive research in pursuit of additional robust and sensitive markers.

6. Models of Aging in In Vitro Systems

In response to cellular stress or damage, proliferating cells enter in a state of long-term cell cycle arrest. Senescence can be induced in cell culture by using multiple stimuli with known common agents. The known models of senescence are summarized in Table 1.

6.1. Replicative Senescence (RS). With the exception of tumor cells and some stem cells, replicative senescence appears to be a fundamental feature of somatic cells [60]. The first formally described senescence model [2] refers to an irreversible arrest of cell proliferation and altered cell function following multiple cell divisions [61]. Telomere shortening because of multiple cell passages has been considered a plausible mechanism [23, 61]. Replicative senescence is characterized by DNA double-strand breaks, with activated ataxia telangiectasia mutated (ATM), and/or ATM and RAD3-related (ATR) mechanisms and their respective mediators, checkpoint kinase 2 (CHK2) and CHK1 [62].

6.2. Stress-Induced Premature Senescence (SIPS). Cellular senescence can be induced by various stresses including oxidative stress. Both chronic and acute oxidative stress protocols were used to induce cellular senescence. Hydrogen peroxide or tert-butyl hydroperoxide is widely used to produce oxidative stress-induced premature senescence within a short period of time [38, 39]. Such induced premature senescent cells display markers that are similar to those from replicative senescent cells. There are many agents that could be used for SIPS, the major classes are cytokines, oxidizing agents, hyperoxia, and copper. Although oxidizing agents work partly through DNA damage, other cellular components such as mitochondria are also affected. In the acute protocol, a single stress dose will inhibit the growth of a fraction of cells with others more or less unharmed. But in the chronic protocol, cells are exposed to repeated stresses, with a dose every day or every other day, allowing to minimize unharmed cells and increasing chances of cells undergoing senescence [63–65]. Thus, SIPS could be a good model to study heterogeneity of aging at the cellular level.

6.3. DNA Damage-Induced Senescence (DDR). Depending on the treatment protocol and dose, DNA damage response (DDR) can induce senescence [66]. Different types of DNA-damaging agents including cancer drugs such as bleomycin or doxorubicin are used to induce this
type of senescence. The DNA damage response is initiated by the activation of the PI(3)K- (phosphatidylinositol-3-OH-kinase-) like kinases ATM, ATR (ATM and RAD related), and DNA-PKcs (DNA-dependent protein kinase catalytic subunit) [62]. These kinases also halt progression through the stages of cell cycle by activating the effector kinases (checkpoint kinase) CHK2 and CHK1 [62]. Finally, checkpoint enforcement results from multiple signaling pathways such as p53 and the cell division cycle 25 phosphatases. Slower p53 induction upon phosphorylation by DDR kinases leads to its stabilization and enhanced ability to induce the transcription of p21 which results in a stable cell cycle arrest [62, 67].

6.4. Oncogene-Induced Senescence (OIS). Oncogene activation is a hallmark of cancer; however, oncogene activation in a normal cell induces cellular senescence [68]. Oncogene-evoked senescence was first discovered following expression of an oncogenic form of Ras in normal human fibroblasts [69]. This process resembles replicative senescence. A sustained antiproliferative response is due to oncogenic signaling resulting from mutation of an oncogene or the inactivation of a tumor-suppressor gene. The activation of oncogenes, such as Ras or B-Raf proto-oncogene, serine/threonine kinase (BRAF), or the inactivation of tumor suppressors, such as PTEN, will result in OIS [23, 70, 71]. Specifically, OIS is established independently of any telomere attrition or dysfunction [72]. So, atypical activation of signaling pathways and positive cell cycle regulators may lead to the buildup of DNA damage, and the resulting cellular senescence [72].

6.5. Mitochondrial Dysfunction-Associated Senescence (MiDAS). The role of mitochondrial damage in cellular senescence has been well characterized using cell cycle arrest as the main marker of senescence [73]. Very little information about the secretory phenotype in conjunction mitochondrial damage-induced senescence is available. However, a recent study describes senescence induced by multiple types of mitochondrial dysfunction lacks a wide number of cytokines secreted during canonical senescence such as IL-1α, IL-1β, IL-6, and IL-8 [74]. This secretory phenotype, controlled by NAD-AMPK-p53 axis, appears to be characteristic of this type of senescence [74]. In addition, it was demonstrated that canonical triggers of cellular senescence, when combined with mitochondrial dysfunction, results in a senescence response that also lacks the abovementioned cytokines, suggesting that mitochondrial damage is superior to nuclear damage regarding the inhibition the cytokines [74].

6.6. Epigenetically Induced Senescence (EIS). DNA methylation changes and histone modification have been observed during cellular senescence. Accordingly, treating cells with epigenetic modifiers that inhibit DNA methyltransferases (5-aza-2′-deoxycytidine), or histone deacetylases (sodium butyrate, trichostatin A) or histone acetyltransferases (curcumin, C646), and histone methyltransferases (BRD4770) are also known to cause senescence [75].

7. Cellular Senescence during Ocular Aging and Age-Related Diseases

Aging is considered one of the most obvious predisposing factors for the development of AMD because prevalence of this disease rises in those over 60. With aging, the human retina undergoes various structural and physiologic changes [80]. Several independent studies suggest senescence contributes to the development of many ocular diseases (Table 2). Aging has been associated with fewer retinal neurons along with numerous age-related quantitative alterations such as decreased areas of dendritic and axonal arbors and decreased density of cells and synapses [81]. One study found that retinal pigment epithelium (RPE) cells were lost in large numbers in the periphery of the human retina [82] while a second study reported overall RPE to photoreceptor ratio dropped with age throughout the retina [83]. Furthermore, protein levels of canonical senescence markers such as p16, p21, and p53 were shown to increase in the RPE isolated from aged human donors (84-86 years) [84]. RPE cells show signs of senescence when grown in vitro for a prolonged period [85]. SA-β-gal positivity of RPE cells has also been reported in the human retina and monkey retina [86]. Neurons, but not neuroglia and blood vessels undergo cellular senescence in the aged human retina [42]. Aging causes loss of retinal neurons, including rod photoreceptors, retinal ganglion cells (RGCs), and rod bipolar cells [82, 86, 87]. In addition, intracellularly, lipofuscin deposits in the RPE, which could be a potential inducer of reactive

---

**Table 1: In vitro senescence models.**

| Senescence model                              | Abbreviation | Method of induction                                      | References |
|-----------------------------------------------|--------------|---------------------------------------------------------|------------|
| Replicative senescence (RS)                   | RS           | Short telomeres, linked to excess rounds of cell division | [2, 37]    |
| Stress-induced premature senescence (SIPS)    | SIPS         | H2O2, t-BH, cytokines, oxidizing agents, hyperoxia, copper, UV irradiation | [37–39, 64, 65] |
| DNA damage response- (DDR-) induced senescence| DDR          | Bleomycin or doxorubicin, gamma irradiator              | [37]       |
| Oncogene-induced senescence (OIS)             | OIS          | Activation and/or overexpression of oncogenes           | [69, 76]   |
| Mitochondrial dysfunction-associated senescence (MiDAS) | MiDAS | Inhibiting mitochondrial SIRT3                           | [74]       |
| Epigenetically induced senescence             | EIS          | 5-Aza-2′-deoxycytidine, sodium butyrate, trichostatin A, curcumin, C646, BRD4770 | [27, 77–79] |
Age-related macular degeneration (AMD) & RPE senescence is associated with the pathology & N/A [38, 86, 100]
Wet AMD & Macrophage senescence impairs cholesterol efflux and promotes neovascular AMD & N/A [101]
Glucoma & Senescent cells in the outflow pathway; retinal ganglion cell senescence & N/A [90, 95, 102]
Experimental ocular hypertension & Senescence of retinal ganglion cells & [102]
Cataracts & Senescence in lens epithelial cells & NA [103, 104]
Retinal microaneurysm & Neurons and blood vessels undergo cellular senescence in the retina & N/A [42]
Fuchs endothelial dystrophy (FED) & Corneal endothelial cells (HCEC) senescence & Kojic acid [105, 106]
Birdshot Uveitis & Shortening of telomere length in peripheral leukocytes. & N/A [107]
Diabetic retinopathy & Endothelial cell senescence & N/A [108–110]
Hyperglycemia-induced retinal microangiopathy & Senescence of the retinal microvasculature, RPE, and ganglion cell layer (GCL) type 1 diabetic rat model & N/A [40]

Oxidative Medicine and Cellular Longevity

8. Cell Senescence Signaling Pathways

Many molecules can work alone or in combination and make the cells senescent via p16INK4a/Rb (retinoblastoma protein), p53/p21, and likely other pathways. Cellular senescence is a state of stable cell cycle arrest and the onset and maintenance of the senescent state involve action of two major pathways, the p16INK4a/Rb pathway and the p19Arf/p53/p21Cip1 pathway [111]. The p16INK4a is a CDK (cyclin-dependent kinase) inhibitor that accumulates in the cell as the number of cell divisions increase. Independent of the p53/p21Cip1 pathway, the p16INK4a/Rb pathway is considered to be the primary pathway leading to the development of senescence in cells [112]. Cellular senescence induced by oxidative stress is mainly through the p16INK4a/Rb pathway. Oxidative stress enhanced the nuclear expression of p16 which can bind to CDK4/6, thus inhibiting the phosphorylation of the retinoblastoma protein Rb and prevent the transcription factors E2F from activating, thereby inhibiting the expression of its regulatory site genes. The mechanism of cells entering the cell cycle from G1 stage to the S stage is prevented, thus inhibiting cell proliferation, and ultimately leading to cell senescence.

Telomere-damaged senescent cells function mainly through the p53/p21Cip1 pathway. When cells are stressed, they can cause high expression of p16 protein. This can lead to the phenotype associated with cell senescence and growth arrest; formation of senescence-associated heterochromatin sites and maintenance of the p16INK4a/Rb pathway is no longer required. p53 is a transcription factor involved in the regulation of an array of cellular processes, including metabolic adaptation, DNA repair, cell cycle arrest, apoptosis,
and senescence (see Bourgeois and Madl, [113] for a review). Several independent studies using p53 inhibitors, p53 antisense oligonucleotides, or homozygous deletion mutants demonstrated a role for p53 in cellular senescence [114]. The p53 protein in the p53/p21Cip1 pathway is a common tumor suppressor protein, which is inactivated in many tumors and upregulated in senescent cells. The ubiquitin ligase MDM2 (murine double minute 2) can promote the degradation of p53 by related proteases or directly inhibit the activity of p53 protein. The p19Arf protein can bind to and inhibit MDM2 activity. When there is damage in the DNA molecule, the upregulated p19Arf protein inhibits MDM2 and activates p53. The p53 then acts downstream p21Cip, inhibits RB phosphorylation, and thus cannot bind to E2F. Blocking cell cycle at the G1 phase makes the cells enter into the senescence state.

9. Cellular Senescence and the Role of SASPs

Multiple stressors induce senescence, some even with shared effects that can also drive multiple phenotypes and pathologies associated with aging. Many studies have provided clear evidence that an array of bioactive molecules are released by senescent cells, called SASP [14]. As mentioned earlier, these include chemokines, cytokines, metalloproteases, and growth factors which can act through both autocrine/paracrine pathways and can affect neighboring cells [115]. Although SASP is generally considered proinflammatory, the true microenvironmental impact and composition of SASP may vary according to cell types (i.e., fibroblasts/epithelial, normal/cancerous) and senescence-triggering stimuli (i.e., replicative senescence, DNA damage-induced senescence, oncogene-induced senescence) [14, 116, 117]. It is now evident that SASP functionally links senescence to various biological processes including tissue regeneration and remodeling, embryonic development, inflammation, and tumorigenesis. Based on the mechanism of action, SASP factors can be classified [118] as (1) receptor mediated, which includes interleukins IL-6, IL-8, and IL-1α; chemokines GROα, GROβ, CCL-2, CCL-5, CCL-16, CCL-26, and CCL-20; and the growth factors VEGF, HGF, FGF, TGF-β, and GM-CSF [119, 120]; (2) regulatory molecules such as tissue inhibitors of metalloproteases (TIMP), the plasminogen activator inhibitor (PAI), and insulin-like growth factor-binding proteins (IGFBP); (3) directly acting such as matrix metalloproteases MMP-1, MMP-10, MMP-3 and serine proteases: the tissue plasminogen activator (tPA) and urokinase plasminogen activator (uPA). Several in vitro and in vivo studies have attributed the multifunctions of the SASP to individual protein components. For example, out of the SASPs, IL-6, IL-8, and CCL2 enhance tumor cell proliferation [14, 121]; VEGF promotes angiogenesis [122]; IL-6, IL-8, IGFBP7, and PAI-1 augment senescence [119–124]. It was reported that the multifunctional cytokines such as TGF-β family ligands, CCL2, and VEGF evoke cellular senescence [125] while PDGF-AA promotes wound healing [11, 126]. In senescent cells, many of the SASP factors discussed above are activated at the transcriptional level [119, 120, 127]. However, many SASP bioactive factors are able to induce inflammation, disrupt tissue architecture, and enhance malignant transformation [128, 129]. Of note, the inhibition of the SASPs such IL-6 or IL-8 only partially blocks paracrine senescence progression suggesting the involvement of alternate pathways [130, 131].

Recently, increasing evidence suggests that extracellular vesicles (EVs) released from senescent cells are unique and are involved in regulating the phenotype of recipient cells the same way as SASP bioactive molecules [132–136]. Hence, the EVs secreted from senescent cells, (senescence-associated EVs), appear to be a novel SASP factor [137–140].

There are reports demonstrating increased EV secretion and changes in the compositions of EVs with stress [141–145]. Further, the expression of the exosome markers CD63 and LAMP2 showed a significant increase in older retinal pigment epithelial tissue [146]. It is also known that the secretion of EVs increased in human RPE cells rendered senescent by the DNA-damaging agent doxorubicin [144]. However, not much is known about the role that EVs play as SASP mediators in the senescent microenvironment. The miRNA components of senescent exosomes are studied in some cell types but, aside from protumorigenic effects [134], the proteomic content and function of exosomes and small EVs secreted by senescent cells are not well studied. A comparative proteomic analysis of EVs secreted from control and DXR-induced senescent RPE cells found that EVs secreted from senescent cells showed a markedly altered protein composition [144]. Paracrine senescence via the SASP has been previously described as an important mechanism during senescence [125, 147], although these studies do not differentiate between the effect of soluble factors secreted by the cells and EVs released. Furthermore, a recent study in human primary fibroblasts provides evidence that both the soluble factors and sEVs are responsible for mediating paracrine senescence [148]. An in-depth mass spectrometric analysis of the published protein composition of soluble factor of senescence [125] and sEV proteomics [148] shows little correlation between both fractions, suggesting that although the downstream signaling is similar, the triggers inducing senescence are diverse. A comprehensive proteomic database of soluble and exosome SASP factors (SASP Atlas), originating from multiple senescence inducers and cell types has appeared recently [149]. The protein cargo of exosomes/EVs released by senescent cells was significantly higher and many protein markers will likely be specific to cell type and originating stimulus when compared to quiescent control cells [149]. Mitsuhashi et al. [150] reported that the levels of IL-6 and IL-12 mRNAs in macrophage-derived exosomes from older subjects are higher than those from younger subjects. Furthermore, there is evidence that miRNAs that can regulate cellular senescence are contained in EVs [151, 152]. In addition, mounting evidence suggests that senescence-associated EVs are involved in pathology as well as senescent cells can impact age-related stem cell dysfunction via EVs [132, 143, 145, 153].

10. Role of Mitochondrial ROS in the Induction of Senescence

It is well known that both intracellular and extracellular ROS have been shown to contribute to the induction of
senescence. Mitochondria produce ROS as a byproduct of electron leak along the electron transport chain during cellular respiration [154]. Hydrogen peroxide (H$_2$O$_2$), which is a major endogenous ROS, is a potent inducer of cellular senescence. Work from our laboratory has documented that H$_2$O$_2$ treatment induced senescence in human RPE cells [38, 39]. ROS have also been shown to act as signaling molecules during senescence, stabilizing the cell cycle arrest. ROS contribute to initiating cellular senescence and progression by either directly damaging mitochondrial DNA (mtDNA) or in interaction with modifications of the telomerase reverse transcriptase enzyme, a catalytic subunit of the enzyme telomerase and the p53 and Ras pathways activity [21]. Dysfunctional mitochondria release multiple damage-associated molecular patterns (DAMPs), such as ATP, ROS, and mtDNA, activating the NLRP3 inflammasome, which in turn trigger the proteolytic maturation of proinflammatory cytokine precursors, such as IL-1β, and leads to the activation of the NF-κB pathway, supporting senescence biogenesis [155]. In contrast, interventions which reduce mitochondrial ROS such as nicotinamide mononucleotide (NAD) [156] and mitochondrial-targeted antioxidant MitoQ [157, 158] have been shown to prevent telomere dysfunction and prevent senescence. NAD treatment via intravital administration in mice also preserves NAD+ and prevents RPE senescence [156]. We have demonstrated that H$_2$O$_2$-induced senescence altered mitochondrial functions and treatment with a mitochondria-derived peptide, humanin, prevented mitochondrial ROS and delayed cellular senescence [39]. ROS also plays a role as a signaling factor in downstream senescence effector pathways [159]. In addition, canonical markers regulating major senescence pathways such as p16, p21, and p53 are elevated in response to increased ROS [39, 160] suggesting that ROS in senescent cells enhanced the cell cycle arrest characteristic of the senescence phenotype [159]. On the other hand, it is suggested that mitochondrial ROS generation may not necessarily be the primary cause of cellular senescence [161]. The senescence phenotype induced by hyperoxia was not blocked either in the mitochondrial SOD2 or catalase overexpressed human lung fibroblasts suggesting the ROS formed in the cytosol alone can induce senescence [161]. Of note, mitochondrial ROS can damage nuclear DNA and thus induce senescence [159]. Depletion of mitochondrial DNA (mtDNA), knockdown of mitochondrial sirtuin-3 (SIRT3), or inhibition of the electron transport chain can induce mitochondrial dysfunction-associated senescence (MiDAS) [74]. It was reported that in MiDAS, pyruvate, but not an antioxidant, prevented MiDAS [74]. Further, no evidence of DNA damage was observed but rather decreased NAD+/NADH ratios caused by MiDAS [74].

11. Energy Metabolism and Cellular Senescence

Mitochondria are the principal cellular organelles responsible for ATP production, calcium regulation, biosynthetic processes, and apoptotic regulation. It is well established that not only cell size but also mitochondrial mass increases significantly in senescent cells (Table 3). Senescent cells have been observed in the eye specifically in the neuronal, endothelial, and RPE cells [42, 86] and it is critical to understand their participation in energy metabolism during aging as well as the progression of various retinal degenerative diseases.

A strong link between mitochondrial metabolism and the senescent state has been proposed [162]. Acute oxidative stress can cause increased ROS production which is linked to mitochondrial oxidative damage, a reduction in mitochondrial copy number, and decreased mitochondrial respiration and ATP production in RPE cells [39, 163–165]. Repeated exposure stress can also induce ROS which in turn can induce and regulate cellular senescence and can cause major changes in the metabolome [166]. In particular, an increase in mitochondrial oxygen consumption and oxidative phosphorylation have been reported in oncogene-induced senescence in human fibroblasts [166, 167], oxidative stress-induced senescence [50, 168], therapy-induced senescence in lymphoma [169], and DNA damage-induced senescence [50]. However, in replicative senescence, an impairment of mitochondrial function and increased glycolysis has been described [50, 170]. Thus, it can be hypothesized that senescent cells follow different bioenergetic phenotypes, depending on the stimuli which trigger senescence induction. In particular, replicative senescence in primary human mammary epithelial cells is accompanied by a marked inhibition of nucleotide synthesis without any alteration in glycolysis. These findings demonstrate that inhibition of nucleotide synthesis plays a causative role in the establishment of replicative senescence [171].

12. Mitochondrial Retrograde Signaling and Senescence

Mitochondrial-to-nuclear signaling has gained much attention in recent years. Retrograde signaling is a mitochondrial-to-nuclear signal transduction pathway by which defective mitochondria communicate with the nuclear genetic compartment [178, 179]. When the oxidative and metabolic activities of mitochondria are altered, it communicates with the nucleus via mitochondrial retrograde signaling. An evidence for this has been reported in mitochondrial damage-associated conditions such as neurodegeneration and cardiovascular diseases [180, 181].

The retrograde signaling involves multiple factors [181] and these factors mainly activate cytosolic mediators through interactions with small molecules (e.g., Ca2+, ROS, NAD+/NADH ratio) and transmit signals into the nucleus [182, 183]. These mitochondrial signals modulate the gene expression of transcription factors, (NRF1, NRF2, Sirt1, mTOR, PPARy, Sp1, CREB) and members of the PGC-1 family of regulated coactivators (PGC-1α, PGC-1β, and PRC) [184]. These reprogrammed transcripts could restore mitochondrial function, activate alternative energy pathways, and prepare the cells for death, senescence, or proliferation [181, 185]. Thus, retrograde signaling-mediated transcriptional reprogramming could play a role in senescence and aging. Increasing evidence indicate that mitochondrial short open reading frame- (sORF-) derived peptides are potent and evolutionarily conserved mitochondrial signals could affect
| Cell type                          | Source of senescence | Mitochondrial mass | Oxidative phosphorylation | Glycolysis | Mitochondrial ATP production | References |
|-----------------------------------|----------------------|--------------------|---------------------------|------------|-------------------------------|------------|
| Human MRC5 fibroblasts            | RS                   | Increased          | Increased                 | Increased  | Decreased                     | [172]      |
| Human foreskin fibroblasts        | RS                   | Increased          | Increased                 | Increased  | Increased                     | [169]      |
| Human dermal fibroblasts.         | RS                   | No change          | No change                 | Increased  | No change                     | [50]       |
| Human dermal fibroblasts.         | Doxorubicin          | Increased          | Increased                 | No change  | Increased                     | [50]       |
| Human foreskin fibroblasts        | Doxorubicin          | Increased          | Increased                 | Increased  | Increased                     | [169]      |
| Human diploid IMR90 fibroblasts   | Oncogenic Ras-induced senescence (OIS) | Increased | Decreased                 | -          | Decreased                     | [56]       |
| Human Dermal Fibroblasts          | Oncogene-induced senescence (OIS) | NA                | Increased                 | -          | -                             | [167]      |
| Human fetal lung fibroblasts      | Oncogene-induced senescence (OIS) | -                 | Increased                 | -          | -                             | [166]      |
| Human fibroblasts                 | Radiation induced    | -                  | No change                 | Increased  | -                             | [173]      |
| Mouse melanoma B16-F1 cell line   | Temozolomide (genotoxic agent) | Increased | Increased                 | Decreased  | increased                     | [174]      |
| HEI-OC1 auditory cells            | SIPS (H$_2$O$_2$)    | Decreased          | -                         | No change  | -                             | [175]      |
| Human lung fibroblasts            | SIPS (H$_2$O$_2$)    | -                  | Increased                 | -          | Increased                     | [176]      |
| Human lung and cardiac fibroblast cells | SIPS (nucleoside analogs) | Increased | Increased                 | -          | Increased                     | [177]      |
| Human disc cells                  | SIPS                 | Increased          | Increased                 | -          | Increased                     | [168]      |
| Human fibroblasts                 | $\gamma$ radiation   | -                  | No change                 | Increased  | -                             | [173]      |

RS: replicative senescence; OIS: oncogene-induced senescence; SIPS: stress-induced premature senescence.
various physiological processes. In support, we have demonstrated that the first mitochondria-derived peptide humanin, transcribed and translated as short ORFs from the 16S rRNA of mtDNA, delayed oxidative stress-induced senescence in RPE cells (Figure 2) [39]. Whether this MDP has a role in the regulation of nuclear factors needs to be studied. However, it has been shown that another MDP, MOTS-c, translocates to the nucleus and regulates nuclear gene expression following metabolic stress via AMPK pathway [186]. Thus, between the nucleus and the mitochondria, signaling occurs in both directions, and further studies of these pathways would provide in-depth details about senescence and organismal aging [187].

13. Mitochondrial Dynamics and Cellular Senescence

Mitochondrial dynamics, in general, include events such as fission, fusion, and mitophagy [188, 189]. Senescent cells are metabolically active and have the ability to self-integrate and remodel their morphology [189]. Fission and fusion help mitochondria to regulate cellular energy levels, and a regulated balance among these events ensure normal mitochondrial and cellular functions [190]. In particular, fusion and fission proteins MFN1, MFN2, dynamin-related protein 1 (DRP1), mitochondrial fission factor (MFF), and mitochondrial fission 1 protein (FIS1) modulate mitochondrial shape in response to cellular requirements [191]. The mitochondrial fusion is primarily regulated by Mitofusion proteins 1/2 (Mfn1/2), optic atrophy protein 1 (Opa1) [192, 193], and fission by dynamin-related protein 1 (Drp1) and fission 1 protein (Fis1). We have shown that in oxidative stress-induced RPE senescence, mitochondrial fission proteins, FIS1, and DRP1 increased significantly [194]. Altering mitochondrial dynamics including morphology can cause mitochondrial defects and dysfunction could result in cellular senescence [195, 196]. However, additional studies are required to establish the link between mitochondrial morphology, dynamics, and cellular senescence.

14. Mitochondrial Biogenesis and Senescence

It is now appreciated that senescence is accompanied by increased mitochondrial oxidative metabolism, along with increased mitochondrial mass due to increased mitochondrial biogenesis [159, 167, 194, 197, 198]. Mitochondrial biogenesis is a multifactorial process which also involves assembly as well as replication of mtDNA [199]. Despite the complexity of the different signaling pathways that potentially regulate mitochondrial biogenesis, they all use...
the key component of the peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α) [200]. The gene expression of nuclear respiration factors (NRF-1 and NRF-2) and mitochondrial transcription factor A (TFAM), which are transcription factors that initiate the expression of both nuclear subunits of the respiratory chain and proteins involved in mitochondrial DNA transcription and replication, are increased by PGC-1α [162, 184, 201]. The mitochondrial mass and the mRNA levels of PGC1α and NRF-1 were found to increase during replicative senescence [202] and this could be attributed to de novo synthesis of the nuclear transcriptional factors as a compensatory response to increased ROS production and the impaired membrane potential [202]. Overexpression of the PGC-1α in human fibroblasts resulted in an increase of the mitochondrial encoded marker protein COX-II, consistent with the ability of PGC-1 to increase mitochondrial number, and accelerated the rate of cellular senescence [202, 203]. In an idiopathic pulmonary fibrosis model, mammalian target of rapamycin/-peroxisome proliferator-activated receptor-γ complex 1α/β (mTOR/PGC-1α/β) axis is markedly upregulated in senescent lung epithelial cells [198]. Despite significant function of PGC-1α in mitochondrial biogenesis and senescence, only very few studies are found on its role in the retina, though some studies on its role in biogenesis exist [204, 205]. It has been also demonstrated that PGC-1α-deficient mice developed some abnormalities in RPE cells that were associated with their accelerated senescence [200, 206, 207]. A recent study using human ARPE19 cells reported that elevated PGC-1α is essential for maintaining normal autophagic flux [206]. Therefore, more detailed studies are required to establish a direct link for PGC-1α and senescence in AMD pathology.

15. Senolytic Drugs for Targeting Senescent Cells

Because of the adverse nature of senescence in the development of multiple illnesses, disrupting or preventing senescence can delay health decline during aging. The discovery of senotherapeutic drugs represents a developing and highly promising field of current research for new therapies. Inhibition of major pathways or disruption of p53 and p16, p21, have all been shown to have a significant benefit in aging phenotypes but they can increase the occurrence of cancer [208–211]. Therefore, selective removal of senescent cells could be the safer route to target senescence. Senolytics are drugs that selectively target senescent cells, not a molecule or a single biochemical pathway, by inducing apoptosis of senescent cells [212]. Effective use of potential senolytics of natural or synthetic molecules that target fundamental aging processes into clinical practice could be transformative. Age-related increase in senescent cells was reported in the skin tissue of monkeys and humans [15, 213]. The first senolytics identified were dasatinib and quercetin; their combination treatment reduced senescent cell burden in chronologically aged, radiation-exposed, and progeroid Ercc1Δ/Δ mice (a mouse model of a human progeroid syndrome) [214]. These results demonstrated the potential of selectively targeting senescent cells and the efficacy of senolytics for alleviating symptoms of age-related diseases and extending health span. Since then, several senolytics, such as navitoclax, 17-DAG, and a peptide that targets the Bcl-2- and p53-related senescent cell anti-apoptotic pathways (SCAPs), have been shown to be effective in reducing senescent cells in mice as evidenced by decreasing senescent cell indicators (see reviews by Sun et al. [215] and Knoppert et al. [216] for a complete list). Following the discovery of dasatinib and quercetin, the next senolytic compound to emerge was navitoclax (ABT-263), a small molecule belonging to Bcl-2 family protein inhibitor. ABT-263 selectively binds to Bcl-2, Bcl-XL, and Bcl-w and prevents their binding to the apoptotic effectors Bax and Bak proteins [217–219]. In mouse models of atherosclerosis and neurodegeneration, ABT-263 eliminated dysfunctional senescent cells from atherosclerotic plaques and brain tissue, respectively, substantially inhibiting the progression of key disease phenotypes [220, 221]. After the discovery as a senolytic agent, ABT-263 has been extensively used to study the mechanisms of aging in several animal model systems. For example, in a model of pulmonary fibrosis, treatment of the irradiated mice with ABT-263 after persistent disease had developed reduced senescent cells and reversed the disease [222]. Fisetin [223] is another flavonoid with multipotent properties identified as a novel senolytic molecule. Acute or intermittent treatment of progeroid and old mice with fisetin reduced the biomarkers of senescence in multiple tissues, restored tissue homeostasis, reduced age-related pathology, and extended median and maximum lifespan [224]. A new class of drug candidates with senolytic properties which are inhibitors of heat-shock protein HSP90 has been discovered [225]. Multiple treatment with the HSP90 inhibitor 17-DAG significantly delayed onset of different age-related symptoms in progeroid mice, leading to an overall health span improvement [225]. In a p16-3MR transgenic mouse model, selective depletion of senescent cells by the small-molecule chemical UBX0101 reduced the development of posttraumatic osteoarthritis by creating a proregenerative microenvironment [226]. Piperlongumine (PL) is a biologically active alkaloid and a recently identified senolytic agent which can selectively kill senescent cells by targeting oxidation resistance 1 (OXR1) to mediate PL senolytic activity [205]. The multicenter Intervention Testing Program by the National Institute for Aging has identified five drugs that increase lifespan in genetically heterogenous mice, including rapamycin, acarbose, nordihydroguaiaretic acid, 17-α-oestradiol, and aspirin [227]. Recent mechanistic studies show that stimulated by cytosolic DNA, active cyclic GMP-AMP synthase-stimulator of interferon gene (cGAS-STING) pathway triggers inflammation and plays a role in the development of senescence [228]. Based on these findings, it was hypothesized that blocking STING pathway could be a potential therapeutic strategy to prevent senescence-associated human diseases [229].

All the preclinical animal studies in different disease models with an array of senolytic agents provide confidence in bringing senolytic agents into clinical trials. In an open-label phase 1 pilot study, the first clinical trial of senolytics, dasatinib (D)+quercetin (Q) improved physical function in
patients with idiopathic pulmonary fibrosis (IPF), a fatal senescence-associated disease and diabetic kidney disease [230, 231]. D+Q decreases p16INKA, p21, and SASP factors, including IL-1α, IL-6, MMP-9, and MMP-12 [230]. The senolytic drug UBX0101 was developed to treat osteoarthritis of the knee (ClinicalTrials.gov Identifier: NCT03513016). Another drug, UBX1967, a Bcl-2 family inhibitor specifically tailored for age-related diseases of the eye, including neovascular age-related macular degeneration, proliferative diabetic retinopathy, and diabetic macular edema, is also progressing to human testing [232].

However, though the initial studies regarding senolytics show positive signs, still there are concerns regarding their effectiveness as therapies. For instance, it has been reported that senescent cells reappeared after cessation of senolytic treatment in a model of osteoarthritis [226]. Although a brief disruption of prosurvival pathways is sufficient to kill senescent cells, they are very effective only when administered intermittently [214]. Further, the senescence program considerably differ among cells/tissues, increasing the possibility of finding cell-/tissue-specific senolytics. With all these, targeting senescence using senolytics or by other strategies could not only ease specific diseases but also considerably improve the general health span of aged individuals.

16. Future Directions

The body of work cited in this review implicates the role of senescent cells in tissues from aged samples as one of the contributing causes of many age-related diseases such as lung disease, cardiovascular diseases, and arthritis, but information on the role of senescent cells in ocular diseases is sparse. There is an ongoing debate whether or not senescent cells found in aged animal models contribute in a significant way to diseases. At the same time, small-molecule senolytic drugs are being developed for treatment of age-related diseases and some drugs are under testing or in clinical trials. The following issues/questions need to be considered before senolytic drug treatment becomes a valuable tool in disease prevention.

(i) Senescent cells are heterogeneous, featured by different characteristics and could follow different pathways to avoid apoptosis [233]. Further, the senescent cell phenotype is dynamic and can change at the time of senescence or various points after senescence occurs. Therefore, there is no single senolytic/SASP inhibitor that could target all the senescent cells. Characterizing those heterogeneous cells using cell-specific markers using multiple approaches, such as experimental and bioinformatics, could highly advance our understanding of senescence and provide new strategies for designing therapy.

(ii) Senescent cells undergo extensive genome remodeling and changes in gene expression, which are poorly understood. Therefore, understanding the mechanisms responsible for these differences in gene expression and their role to senescence acquisition and SASPs would greatly benefit designing therapies. It is also worthwhile to explore the role of key epigenetic regulators that lead to the SASP and target them directly to prevent senescence.

(iii) Since senescent cells have many subpopulations in the same tissue, a single drug is unlikely to induce apoptosis to all of them. Therefore, in addition to senolytic drugs, SASP inhibitors, another group of molecules that show promise as treating age-related diseases, are also currently being tested. However, the components of the SASP vary based on the cell type from which senescent cells developed [234]. SASP components also vary in the presence of many drugs, and the regulation is segmental: not all SASP components are regulated, and hence SASPs could be modifiable [234]. Thus, it is important to learn how SASPs change at different stages of senescence, and how the SASP factors differ from tissue damage signals. Use of senolytic cocktail or combination therapy would be a better approach in fighting senescence-associated diseases in this regard.

(iv) It is now widely accepted from cellular studies that mitochondrial dysfunction plays a major role in senescence. Whether stress-induced or age-related mitochondrial dysfunction cause senescence in vivo remains to be studied in detail. Given the complexity of mitochondria and their involvement in multiple processes and functions, it is highly likely. Therefore, it is of major importance to further investigate the molecular processes behind the role of mitochondria in aging, and their potential to serve as targets for therapeutic interventions.

(v) Multiple animal models are required to test potential senolytic drugs/senolytic cocktails and to understand the off-target effects of senolytic agents [56, 95, 102]. While genetically modified mice such as p16 transgenic mice [56] or pharmacological manipulations are available for most diseases, more work on additional models is required. In other words, it is desirable that senescence-associated disease animal models are developed in which senescent cells can be tracked in tissues of interest, and from which senescent cells can be cleared using the potential drugs.

(vi) Finally, research on understanding the mechanism of senescence from ocular cells and tissues is just beginning. IND-enabling studies of senolytic drugs for diseases such as AMD have recently been initiated [232]. The success of such investigations, although promising, will depend on a greater understanding of the mechanism of disease progression in the eye to develop optimal therapies that target the primary defect in the retina.

Conflicts of Interest

The authors declare that there is no conflict of interest regarding the publication of this paper.
Acknowledgments

This work was supported by funding from the Stephen J. Ryan Initiative for Macular Research (RIMR). We thank Dr. Chandra Nagineni, National Cancer Institute, for helpful discussions.

References

[1] J. Campisi and F. d’Adda di Fagagna, “Cellular senescence: when bad things happen to good cells,” Nature Reviews Molecular Cell Biology, vol. 8, no. 9, pp. 729–740, 2007.
[2] L. Hayflick and P. S. Moorhead, “The serial cultivation of human diploid cell strains,” Experimental Cell Research, vol. 25, no. 3, pp. 585–621, 1961.
[3] B. G. Childs, M. Durik, D. J. Baker, and J. M. van Deursen, “Cellular senescence in aging and age-related disease: from mechanisms to therapy,” Nature Medicine, vol. 21, no. 12, pp. 1424–1435, 2015.
[4] D. Muñoz-Espín, M. Cañamero, A. Maraver et al., “Programmed cell senescence during mammalian embryonic development,” Cell, vol. 155, no. 5, pp. 1104–1118, 2013.
[5] I. Sturmlechner, M. Durik, C. J. Sieben, D. J. Baker, and J. M. van Deursen, “Cellular senescence in renal ageing and disease,” Nature Reviews Nephrology, vol. 13, no. 2, pp. 77–89, 2017.
[6] M. Storer, A. Mas, A. Robert-Moreno et al., “Senescence is a developmental mechanism that contributes to embryonic growth and patterning,” Cell, vol. 155, no. 5, pp. 1119–1130, 2013.
[7] J. Campisi, “CANCER: Suppressing cancer: the importance of being senescent,” Science, vol. 309, no. 5736, pp. 886–887, 2005.
[8] D. G. A. Burton and V. Krizhanovsky, “Physiological and pathological consequences of cellular senescence,” Cellular and Molecular Life Sciences, vol. 71, no. 22, pp. 4373–4386, 2014.
[9] D. J. Baker, T. Wijshake, T. Tchkonia et al., “Clearance of p16\(^{\text{INK4A}}\)-positive senescent cells delays ageing-associated disorders,” Nature, vol. 479, no. 7372, pp. 232–236, 2011.
[10] D. J. Baker, B. G. Childs, M. Durik et al., “Naturally occurring p16\(^{\text{INK4A}}\)-positive cells shorten healthy lifespan,” Nature, vol. 530, no. 7589, pp. 184–189, 2016.
[11] M. Demaria, N. Oltani, S. A. Youssef et al., “An essential role for senescent cells in optimal wound healing through secretion of PDGF-AA,” Developmental Cell, vol. 31, no. 6, pp. 722–733, 2014.
[12] V. Krizhanovsky, M. Yon, R. A. Dickins et al., “Senescence of activated stellate cells limits liver fibrosis,” Cell, vol. 134, no. 4, pp. 657–667, 2008.
[13] B. Ritschka, M. Storer, A. Mas et al., “The senescence-associated secretory phenotype induces cellular plasticity and tissue regeneration,” Genes & Development, vol. 31, no. 2, pp. 172–183, 2017.
[14] J. P. Coppé, C. K. Patil, F. Rodier et al., “Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor,” PLoS Biology, vol. 6, no. 12, pp. 2853–2868, 2008.
[15] J. C. Jeyapalan, M. Ferreira, J. M. Sedivy, and U. Herbig, “Accumulation of senescent cells in mitotic tissue of aging primates,” Mechanisms of Ageing and Development, vol. 128, no. 1, pp. 36–44, 2007.
[16] A. Biran, L. Zada, P. Abou Karam et al., “Quantitative identification of senescent cells in aging and disease,” Aging Cell, vol. 16, no. 4, pp. 661–671, 2017.
[17] F. Rodier and J. Campisi, “Four faces of cellular senescence,” The Journal of Cell Biology, vol. 192, no. 4, pp. 547–556, 2011.
[18] J. Birch, R. K. Anderson, C. Correa-Melo et al., “DNA damage response at telomeres contributes to lung aging and chronic obstructive pulmonary disease,” American Journal of Physiology Lung Cellular and Molecular Physiology, vol. 309, no. 10, pp. L1124–L1137, 2015.
[19] M. Ogrodnik, S. Miwa, T. Tchkonia et al., “Cellular senescence drives age-dependent hepatic steatosis,” Nature Communications, vol. 8, no. 1, p. 15691, 2017.
[20] G. P. Dimri, X. Lee, G. Basile et al., “A biomarker that identifies senescent human cells in culture and in aging skin in vivo,” Proceedings of the National Academy of Sciences, vol. 92, no. 20, pp. 9363–9367, 1995.
[21] J. M. van Deursen, “The role of senescent cells in aging,” Nature, vol. 509, no. 7591, pp. 439–446, 2014.
[22] J. Campisi, “Aging, cellular senescence, and cancer,” Annual Review of Physiology, vol. 75, no. 1, pp. 685–705, 2013.
[23] N. E. Sharpless and C. J. Sherr, “Forging a signature of “in vivo senescence,” Nature Reviews Cancer, vol. 15, no. 7, pp. 397–408, 2015.
[24] V. Myriantopoulos, K. Evangelou, P. V. S. Vasileiou et al., “Senescence and senotherapeutics: a new field in cancer therapy,” Pharmacol & Therapeutics, vol. 193, pp. 31–49, 2019.
[25] A. C. Lloyd, “The regulation of cell size,” Cell, vol. 154, no. 6, pp. 1194–1205, 2013.
[26] H. E. Walters, S. Deneka-Hannemann, and L. S. Cox, “Reversal of phenotypes of cellular senescence by pan-mTOR inhibition,” Aging, vol. 8, no. 2, pp. 231–244, 2016.
[27] M. Narita, S. Núñez, E. Heard et al., “Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence,” Cell, vol. 113, no. 6, pp. 703–716, 2003.
[28] B. Y. Lee, J. A. Han, J. S. Im et al., “Senescence-associated beta-galactosidase is lysosomal beta-galactosidase,” Aging Cell, vol. 5, no. 2, pp. 187–195, 2006.
[29] J. Krishnamurthy, C. Torrice, M. R. Ramsey et al., “Ink4a/Arf expression is a biomarker of aging,” The Journal of Clinical Investigation, vol. 114, no. 9, pp. 1299–1307, 2004.
[30] S. Ressler, J. Bartkova, H. Niederegger et al., “p16INK4A is a robust in vivo biomarker of cellular aging in human skin,” Aging Cell, vol. 5, no. 5, pp. 379–389, 2006.
[31] Y. Liu, H. K. Sanoff, H. Cho et al., “Expression of p16(INK4a) in peripheral blood T-cells is a biomarker of human aging,” Aging Cell, vol. 8, no. 4, pp. 439–448, 2009.
[32] T. Kuijlman and D. S. Peeper, “Senescence-messaging secretome: SMS-ing cellular stress,” Nature Reviews Cancer, vol. 9, no. 2, pp. 81–94, 2009.
[33] J. P. Coppé, P. Y. Desprez, A. Krtolica, and J. Campisi, “The senescence-associated secretory phenotype: the dark side of tumor suppression,” Annual Review of Pathology, vol. 5, no. 1, pp. 99–118, 2010.
[34] A. Helman, A. Klocchendler, N. Azazmeh et al., “p16INK4a-induced senescence of pancreatic beta cells enhances insulin secretion,” Nature Medicine, vol. 22, no. 4, pp. 412–420, 2016.
[55] H. Koch, K. P. Wittern, and J. Bergemann, “In Human Keratinocytes the Common Deletion Reflects Donor Variabilities Rather Than Chronologic Aging and can be Induced by Ultraviolet A Irradiation,” The Journal of Investigative Dermatology, vol. 117, no. 4, pp. 892–897, 2001.

[56] E. Hutter, K. Renner, G. Pfister, P. Stöckl, P. Jansen-Dürr, and E. Gnaiger, “Senescence-associated changes in respiration and oxidative phosphorylation in primary human fibroblasts,” The Biochemical Journal, vol. 380, no. 3, pp. 919–928, 2004.

[57] S. Y. Park, B. Choi, H. Cheon et al., “Cellular aging of mitochondrial DNA-depleted cells,” Biochemical and Biophysical Research Communications, vol. 325, no. 4, pp. 1399–1405, 2004.

[58] R. M. Laberge, D. Adler, M. DeMaria et al., “Mitochondrial DNA damage induces apoptosis in senescent cells,” Cell Death & Disease, vol. 4, no. 7, article e727, 2013.

[59] O. Moiseeva, V. Bourdeau, A. Roux, X. Deschénes-Simard, and G. Ferbeyre, “Mitochondrial dysfunction contributes to oncogene-induced senescence,” Molecular and Cellular Biology, vol. 29, no. 16, pp. 4495–4507, 2009.

[60] S. Hubackova, E. Davidova, K. Rohlenova et al., “Selective elimination of senescent cells by mitochondrial targeting is regulated by ANT2,” Cell Death and Differentiation, vol. 26, no. 2, pp. 276–290, 2019.

[61] A. Ivanov, J. Pawlikowski, I. Manoharan et al., “Lysosome-mediated processing of chromatin in senescence,” The Journal of Cell Biology, vol. 202, no. 1, pp. 129–143, 2013.

[62] K. Contrepois, C. Couderc, B. A. Benayoun et al., “Histone variant H2A.J accumulates in senescent cells and promotes inflammatory gene expression,” Nature Communications, vol. 8, no. 1, article 14995, 2017.

[63] J. Campisi,”The biology of replicative senescence,” European Journal of Cancer, vol. 33, no. 5, pp. 703–709, 1997.

[64] J. Campisi, “Replicative senescence: an old lives’ tale?,” Cell, vol. 84, no. 4, pp. 497–500, 1996.

[65] F. d’Adda di Fagagna, “Living on a break: cellular senescence as a DNA-damage response,” Nature Reviews Cancer, vol. 8, no. 7, pp. 512–522, 2008.

[66] P. Dumont, M. Burton, Q. M. Chen et al., “Induction of replicative senescence biomarkers by sublethal oxidative stresses in normal human fibroblast,” Free Radical Biology & Medicine, vol. 28, no. 3, pp. 361–373, 2000.

[67] O. Toussaint, A. Houbion, and J. Remacle, “Aging as a multi-step process characterized by a lowering of entropy production leading the cell to a sequence of defined stages. II. Testing some predictions on aging human fibroblasts in culture,” Mechanisms of Ageing and Development, vol. 65, no. 1, pp. 65–83, 1992.

[68] O. Toussaint, C. Michiels, M. Raes, and J. Remacle, “Cellular aging and the importance of energetic factors,” Experimental Gerontology, vol. 30, no. 1, pp. 1–22, 1995.
[66] A. Bielak-Zmijewska, G. Mosieniak, and E. Sikora, "Is DNA damage indispensable for stress-induced senescence?", *Mechanisms of Ageing and Development*, vol. 170, pp. 13–21, 2018.

[67] R. Salama, M. Sadaie, M. Hoare, and M. Narita, "Cellular senescence and its effector programs," *Genes & Development*, vol. 28, no. 2, pp. 99–114, 2014.

[68] A. Prieur and D. S. Peep, "Cellular senescence in vivo: a barrier to tumorigenesis," *Current Opinion in Cell Biology*, vol. 20, no. 2, pp. 150–155, 2008.

[69] M. Serrano, A. W. Lin, M. E. McCurrach, D. Beach, and S. W. Lowe, "Oncogenic _ras_ Provokes Premature Cell Senescence Associated with Accumulation of p53 and p16<sup>INK4a</sup>", *Cell*, vol. 88, no. 5, pp. 593–602, 1997.

[70] W. J. Mooi and D. S. Peep, "Oncogene-induced cell senescence–halting on the road to cancer," *The New England Journal of Medicine*, vol. 355, no. 10, pp. 1037–1046, 2006.

[71] C. Chandeck and W. J. Mooi, "Oncogene-induced cellular senescence," *Advances in Anatomic Pathology*, vol. 17, no. 1, pp. 42–48, 2010.

[72] C. J. Jones, D. Kipling, M. Morris et al., "Evidence for a telomere-independent "Clock" limiting RAS oncogene-driven proliferation of human thyroid epithelial cells," *Molecular and Cellular Biology*, vol. 20, no. 15, pp. 5690–5699, 2000.

[73] D. V. Ziegler, C. D. Wiley, and M. C. Velarde, "Mitochondrial effectors of cellular senescence: beyond the free radical theory of aging," *Aging Cell*, vol. 14, no. 1, pp. 1–7, 2015.

[74] C. D. Wiley, M. C. Velarde, P. Lecot et al., "Mitochondrial dysfunction induces senescence with a distinct secretory phenotype," *Cell Metabolism*, vol. 23, no. 2, pp. 303–314, 2016.

[75] V. Petrova, A. K. Velichko, S. V. Rayun, and O. L. Kantidze, "Small molecule compounds that induce cellular senescence," *Aging Cell*, vol. 15, no. 6, pp. 999–1017, 2016.

[76] A. Kilbey, A. Terry, E. R. Cameron, and J. C. Neil, "Oncone gene-induced senescence: an essential role for Runx," *Cell Cycle*, vol. 7, no. 15, pp. 2333–2340, 2008.

[77] W. Shi, A. Hoolie, H. Flaswinkel, M. Stojkovic, E. Wolf, and V. Zakhartchenko, "Induction of a senescent-like phenotype does not confer the ability of bovine immortal cells to support the development of nuclear transfer Embryos," *Biology of Reproduction*, vol. 69, no. 1, pp. 301–309, 2003.

[78] J. Munro, N. I. Barr, H. Ireland, V. Morrison, and E. K. Parkinson, "Histone deacetylase inhibitors induce a senescence-like state in human cells by a p16-dependent mechanism that is independent of a mitotic clock," *Experimental Cell Research*, vol. 295, no. 2, pp. 525–538, 2004.

[79] W. Grabowska, K. Kucharewicz, M. Wnuk et al., "Curcumin induces senescence of primary human cells building the vascularure in a DNA damage and ATM-independent manner," *Age*, vol. 37, no. 1, p. 9744, 2015.

[80] C. Cavallotti, M. Artico, N. Pescosolido, F. M. Leali, and J. Feher, "Age-related changes in the human retina," *Canadian Journal of Ophthalmology*, vol. 39, no. 1, pp. 61–68, 2004.

[81] M. A. Samuel, Y. Zhang, M. Meister, and J. R. Sanes, "Age-related alterations in neurons of the mouse retina," *The Journal of Neuroscience*, vol. 31, no. 44, pp. 16033–16044, 2011.

[82] H. Gao and J. G. Hollyfield, "Aging of the human retina. Differential loss of neurons and retinal pigment epithelial cells," *Investigative Ophthalmology & Visual Science*, vol. 33, no. 1, pp. 1–17, 1992.

[83] C. K. Dorey, G. Wu, D. Ebenstein, A. Garsd, and J. J. Weiner, "Cell loss in the aging retina. Relationship to lipofuscin accumulation and macular degeneration," *Investigative Ophthalmology & Visual Science*, vol. 30, no. 8, pp. 1691–1699, 1989.

[84] E. Chau, C. S. Winborn, and S. Bhattacharya, "Genomic regulation of senescence and innate immunity signaling in the retinal pigment epithelium," *Mammalian Genome*, vol. 26, no. 5–6, pp. 210–221, 2015.

[85] H. Matsunaga, J. T. Handa, A. Aotaki-Keen, S. W. Sherwer, M. D. West, and L. M. Hjelmeland, "Beta-galactosidase histochemistry and telomere loss in senescent retinal pigment epithelial cells," *Investigative Ophthalmology & Visual Science*, vol. 40, no. 1, pp. 197–202, 1999.

[86] K. Mishima, J. T. Handa, A. Aotaki-Keen, G. A. Lutty, L. S. Morse, and L. M. Hjelmeland, "Senescence-associated beta-galactosidase histochemistry for the primate eye," *Investigative Ophthalmology & Visual Science*, vol. 40, no. 7, pp. 1590–1593, 1999.

[87] C. A. Curcio, C. L. Millican, A. D. Allen, and R. E. Kalina, "Aging of the human photoreceptor mosaic: evidence for selective vulnerability of rods in central retina," *Investigative Ophthalmology & Visual Science*, vol. 34, no. 12, pp. 3278–3296, 1993.

[88] J. R. Sparrow and M. Boulton, "RPE lipofuscin and its role in retinal pathobiology," *Experimental Eye Research*, vol. 80, no. 5, pp. 595–606, 2005.

[89] B. T. Gabelt and P. L. Kaufman, "Changes in aqueous humor dynamics with age and glaucoma," *Progress in Retinal and Eye Research*, vol. 24, no. 5, pp. 612–637, 2005.

[90] J. Caprioli, "Glucoma: a disease of early cellular senescence," *Investigative Ophthalmology & Visual Science*, vol. 54, no. 14, p. ORSF60, 2013.

[91] R. S. Harwerth, J. L. Wheat, and N. V. Rangaswamy, "Age-related losses of retinal ganglion cells and axons," *Investigative Ophthalmology & Visual Science*, vol. 49, no. 10, pp. 4437–4443, 2008.

[92] W. Chi, F. Li, H. Chen et al., "Caspase-8 promotes NLRP1/NLRP3 inflammasome activation and IL-1 production in acute glaucoma," *Proceedings of the National Academy of Sciences*, vol. 111, no. 30, pp. 11181–11186, 2014.

[93] J. L. Wiggs, B. L. Yaspan, M. A. Hauser et al., "Common variants at 9p21 and 8q22 are associated with increased susceptibility to optic nerve degeneration in glaucoma," *PLoS Genetics*, vol. 8, no. 4, article e1002654, 2012.

[94] K. P. Burdon, S. Macgregor, A. W. Hewitt et al., "Genome-wide association study identifies susceptibility loci for open angle glaucoma at _TMCO1_ and _CDKN2B-AS1_," *Nature Genetics*, vol. 43, no. 6, pp. 574–578, 2011.

[95] D. Skowronska-Krawczyk, L. Zhao, J. Zhu et al., "_P16INK4a_ Upregulation Mediated by _SIX6_ Defines Retinal Ganglion Cell Pathogenesis in Glaucoma," *Molecular Cell*, vol. 59, no. 6, pp. 931–940, 2015.

[96] J. Wassell, S. Davies, W. Bardsley, and M. Boulton, "The photoreactivity of the retinal age pigment lipofuscin," *The Journal of Biological Chemistry*, vol. 274, no. 34, pp. 23828–23832, 1999.

[97] L. V. Johnson, W. P. Leitner, A. J. Rivest, M. K. Staples, M. J. Radeke, and D. H. Anderson, "The Alzheimer’s A beta -peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular
degeneration,” *Proceedings of the National Academy of Sciences*, vol. 99, no. 18, pp. 11830–11835, 2002.

[98] T. Dentichev, A. H. Milam, V. M. Lee, J. Q. Trojanowski, and J. L. Dunai, “Amyloid-beta is found in drusen from some age-related macular degeneration retinas, but not in drusen from normal retinas,” *Molecular Vision*, vol. 9, pp. 184–190, 2003.

[99] L. Cao, H. Wang, F. Wang, D. Xu, F. Liu, and C. Liu, “Aβ-induced senescent retinal pigment epithelial cells create a proinflammatory microenvironment in AMD,” *Investigative Ophthalmology & Visual Science*, vol. 54, no. 5, pp. 3738–3750, 2013.

[100] C. Liu, L. Cao, S. Yang et al., “Subretinal injection of amyloid-β peptide accelerates RPE cell senescence and retinal degeneration,” *International Journal of Molecular Medicine*, vol. 35, no. 1, pp. 169–176, 2015.

[101] A. Sene, A. A. Khan, D. Cox et al., “Impaired cholesterol efflux in senescent macrophages promotes age-related macular degeneration,” *Cell Metabolism*, vol. 17, no. 4, pp. 549–561, 2013.

[102] R. L. Rocha, V. A. N. Huu, C. P. La Torre et al., “Early Removal of senescent cells protects retinal ganglion cells loss in experimental ocular hypertension,” *Aging Cell*, vol. 19, no. 2, article e13089, 2020.

[103] Q. Fu, Z. Qin, J. Yu et al., “Effects of senescent lens epithelial cells on the severity of age-related cataract in humans: a case-control study,” *Medicine*, vol. 95, no. 25, article e3869, 2016.

[104] Y. Yan, H. Yu, L. Sun et al., “Laminin α4 overexpression in the anterior lens capsule may contribute to the senescence of human lens epithelial cells in age-related cataract,” *Aging*, vol. 11, no. 9, pp. 2699–2723, 2019.

[105] M. Matthaei, H. Meng, A. K. Meeker, C. G. Eberhart, and A. S. Jun, “Endothelial Cdkn1a (p21) overexpression and accelerated senescence in a mouse model of Fuchs endothelial corneal dystrophy,” *Investigative Ophthalmology & Visual Science*, vol. 53, no. 10, pp. 6718–6727, 2012.

[106] X. Wei, D. Luo, Y. Yan et al., “Kojic acid inhibits senescence of human corneal endothelial cells via NF-κB and p21 signaling pathways,” *Experimental Eye Research*, vol. 180, pp. 174–183, 2019.

[107] N. Vazipanah, F. H. Verhagen, A. Rothova et al., “Aberrant leukocyte telomere length in birdshot uveitis,” *PloS One*, vol. 12, no. 5, article e0176175, 2017.

[108] M. C. Thounaajam, R. N. Jadeja, M. Warren et al., “MicroRNA-34a (miR-34a) mediates retinal endothelial cell premature senescence through mitochondrial dysfunction and loss of antioxidant activities,” *Antioxidants*, vol. 8, no. 9, p. 328, 2019.

[109] M. Rojas, T. Lemtalsi, H. A. Toque et al., “NOX2-induced activation of arginase and diabetes-induced retinal endothelial cell senescence,” *Antioxidants*, vol. 6, no. 2, p. 43, 2017.

[110] E. Shosha, Z. Xu, S. P. Narayanan et al., “Mechanisms of diabetes-induced endothelial cell senescence: role of arginase 1,” *International Journal of Molecular Sciences*, vol. 19, no. 4, p. 1215, 2018.

[111] C. M. Beauséjour, A. Krtolica, F. Galimi et al., “Reversal of human cellular senescence: roles of the p53 and p16 pathways,” *The EMBO Journal*, vol. 22, no. 16, pp. 4212–4222, 2003.

[112] T. Kullman, C. Michalagou, W. J. Mooi, and D. S. Peeper, “The essence of senescence,” *Genes & Development*, vol. 24, no. 22, pp. 2463–2479, 2010.

[113] B. Bourgeois and T. Madl, “Regulation of cellular senescence via the FOXO4-p53 axis,” *FEBS Letters*, vol. 592, no. 12, pp. 2083–2097, 2018.

[114] K. Fujita, A. M. Mondal, I. Horikawa et al., “p53 isoforms Δ133p53 and p53β are endogenous regulators of replicative cellular senescence,” *Nature Cell Biology*, vol. 11, no. 9, pp. 1135–1142, 2009.

[115] M. Hoare and M. Narita, “Transmitting senescence to the cell neighbourhood,” *Nature Cell Biology*, vol. 15, no. 8, pp. 887–889, 2013.

[116] A. Freund, A. V. Orjalo, P. Y. Desprez, and J. Campisi, “Inflammatory networks during cellular senescence: causes and consequences,” *Trends in Molecular Medicine*, vol. 16, no. 5, pp. 238–246, 2010.

[117] N. Malaquín, V. Tu, and F. Rodier, “Assessing functional roles of the senescence-associated secretory phenotype (SASP),” *Methods in Molecular Biology*, vol. 1896, pp. 45–55, 1896.

[118] H. O. Byun, Y. K. Lee, J. M. Kim, and G. Yoon, “From cell senescence to age-related diseases: differential mechanisms of action of senescence-associated secretory phenotypes,” *BMB Reports*, vol. 48, no. 10, pp. 549–558, 2015.

[119] J. C. Acosta, A. Loghlen, A. Banito, S. Raguz, and J. Gil, “Control of senescence by CXCR2 and its ligands,” *Cell Cycle*, vol. 7, no. 19, pp. 2956–2959, 2008.

[120] T. Kullman, C. Michalagou, L. C. W. Vredeveld et al., “Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network,” *Cell*, vol. 133, no. 6, pp. 1019–1031, 2008.

[121] M. Ohanna, S. Giuliano, C. Bonet et al., “Senescent cells develop a PARP-1 and nuclear factor-κB-associated secretome (PNAS),” *Genes & Development*, vol. 25, no. 12, pp. 1245–1261, 2011.

[122] J. P. Coppé, K. Kauser, J. Campisi, and C. M. Beauséjour, “Secretion of vascular endothelial growth factor by primary human fibroblasts at senescence,” *The Journal of Biological Chemistry*, vol. 281, no. 40, pp. 29568–29574, 2006.

[123] R. M. Kortlever, P. J. Higgins, and R. Bernards, “Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence,” *Nature Cell Biology*, vol. 8, no. 8, pp. 877–884, 2006.

[124] N. Wajapeyee, R. W. Serra, X. Zhu, M. Mahalingam, and M. R. Green, “Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7,” *Cell*, vol. 132, no. 3, pp. 363–374, 2008.

[125] J. C. Acosta, A. Banito, T. Wuestefeld et al., “A complex secretory program orchestrated by the inflammasome controls paracrine senescence,” *Nature Cell Biology*, vol. 15, no. 8, pp. 978–990, 2013.

[126] M. Rhinn, B. Ritschka, and W. M. Keyes, “Cellular senescence in development, regeneration and disease,” *Development*, vol. 146, no. 20, article dev151837, 2019.

[127] Y. Chien, C. Scoppo, X. Wang et al., “Control of the senescence-associated secretory phenotype by NF-κB promotes senescence and enhances chemosensitivity,” *Genes & Development*, vol. 25, no. 20, pp. 2125–2136, 2011.

[128] B. Ancrile, K. H. Lim, and C. M. Counter, “Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis,” *Genes & Development*, vol. 21, no. 14, pp. 1714–1719, 2007.
[129] A. Sparmann and D. Bar-Sagi, “Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis,” Cancer Cell, vol. 6, no. 5, pp. 447–458, 2004.

[130] N. Herranz, S. Gallage, M. Mellone et al., “mTOR regulates MAPKAPK2 translation to control the senescence-associated secretory phenotype,” Nature Cell Biology, vol. 17, no. 9, pp. 1205–1217, 2015.

[131] R. M. Laberge, Y. Sun, A. V. Orjalo et al., “MTOR regulates the pro-tumorigenic senescence-associated secretory phenotype by promoting IL1A translation,” Nature Cell Biology, vol. 17, no. 8, pp. 1049–1061, 2015.

[132] M. Abbas, L. Jesel, C. Auger et al., “Endothelial microparticles from acute coronary syndrome patients induce premature coronary artery endothelial cell aging and thrombogenicity: role of the Ang II/AT1 Receptor/NADPH oxidase-mediated activation of MAPKs and PI3-kinase pathways,” Circulation, vol. 135, no. 3, pp. 280–296, 2017.

[133] C. Davis, A. Dukes, M. Drewry et al., “MicroRNA-183-5p increases with age in bone-derived extracellular vesicles, suppresses bone marrow stromal (stem) cell proliferation, and induces stem cell senescence,” Tissue Engineering Part A, vol. 23, no. 21-22, pp. 1231–1240, 2017.

[134] M. Takasugi, “Emerging roles of extracellular vesicles in cellular senescence and aging,” Aging Cell, vol. 17, no. 2, article e12734, 2018.

[135] S. Wellner, E. Schraml, M. Wieser et al., “Secreted microvesicular miR-31 inhibits osteogenic differentiation of mesenchymal stem cells,” Aging Cell, vol. 15, no. 4, pp. 744–754, 2016.

[136] C. Borras, C. Mas-Bargues, J. Sanz-Ros et al., “Extracellular vesicles and redox modulation in aging,” Free Radical Biology and Medicine, 2019.

[137] A. O’Loghlen, “Role for extracellular vesicles in the tumour microenvironment,” Philosophical Transactions of the Royal Society B: Biological Sciences, vol. 373, no. 1737, p. 20160488, 2018.

[138] H. Valadi, K. Ekström, A. Bossios, M. Sjöstrand, J. J. Lee, and J. O. Lötving, “Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells,” Nature Cell Biology, vol. 9, no. 6, pp. 654–659, 2007.

[139] D. M. Pegtel, K. Kosmopoulos, D. A. Thorley-Lawson et al., “Functional delivery of viral miRNAs via exosomes,” Proceedings of the National Academy of Sciences, vol. 107, no. 14, pp. 6328–6333, 2010.

[140] M. Pathan, P. Fonseka, S. V. Chitti et al., “Vesiclepedia 2019: a compendium of RNA, proteins, lipids and metabolites in extracellular vesicles,” Nucleic Acids Research, vol. 47, no. D1, pp. D516–D519, 2019.

[141] L. A. Beninson and M. Fleschner, “Exosomes: an emerging factor in stress-induced immunomodulation,” Seminars in Immunology, vol. 26, no. 5, pp. 394–401, 2014.

[142] S. Atienza-Aroca, M. Flores-Bellver, G. Serrano-Heras et al., “Oxidative stress in retinal pigment epithelium cells increases exosome secretion and promotes angiogenesis in endothelial cells,” Journal of Cellular and Molecular Medicine, vol. 20, no. 8, pp. 1457–1466, 2016.

[143] M. Klingeborn, W. M. Dismuke, C. Bowes Rickman, and W. D. Stamer, “Roles of exosomes in the normal and diseased eye,” Progress in Retinal and Eye Research, vol. 59, pp. 158–177, 2017.

[144] M. Takasugi, R. Okada, A. Takahashi, D. Virya Chen, S. Watanabe, and E. Hará, “Small extracellular vesicles secreted from senescent cells promote cancer cell proliferation through EphA2,” Nature Communications, vol. 8, no. 1, p. 15729, 2017.

[145] N. Shah, M. Ishii, C. Brandon et al., “Extracellular vesicle-mediated long-range communication in stressed retinal pigment epithelium cell monolayers,” Biochimica et Biophysica Acta - Molecular Basis of Disease, vol. 1864, no. 8, pp. 2610–2622, 2018.

[146] A. L. Wang, T. J. Lukas, M. Yuan, N. Du, M. O. Tso, and A. H. Neufeld, “Autophagy and exosomes in the aged retinal pigment epithelium: possible relevance to drusen formation and age-related macular degeneration,” PLoS One, vol. 4, no. 1, e1460, 2009.

[147] M. Hoare, Y. Ito, T. W. Kang et al., “NOTCH1 mediates a switch between two distinct secretomes during senescence,” Nature Cell Biology, vol. 18, no. 9, pp. 979–992, 2016.

[148] M. Borghesan, J. Fafán-Labara, O. Eleftheriadou et al., “Small extracellular vesicles are key regulators of non-cell autonomous intercellular communication in senescence via the interferon protein IFITM3,” Cell Reports, vol. 27, no. 13, pp. 3956–3971.e6, 2019.

[149] N. Basisty, A. Holtz, and B. Schilling, “Accumulation of “old proteins” and the critical need for MS-based protein turnover measurements in aging and longevity,” Proteomics, vol. 13, article e1800403, 2019.

[150] M. Mitsuhashi, D. D. Taub, D. Kapogiannis et al., “Aging enhances release of exosomal cytokine mRNAs by Aβ1-42-stimulated macrophages,” The FASEB Journal, vol. 27, no. 12, pp. 5141–5150, 2013.

[151] B. W. van Balkom, O. G. de Jong, M. Smits et al., “Endothelial cells require miR-214 to secrete exosomes that suppress senescence and induce angiogenesis in human and mouse endothelial cells,” Blood, vol. 121, no. 19, pp. 3997–4006, 2013.

[152] K. Weiner-Gorzeli, E. Dempsey, M. Milewska et al., “Overexpression of the microRNA miR-433 promotes resistance to paclitaxel through the induction of cellular senescence in ovarian cancer cells,” Cancer Medicine, vol. 4, no. 5, pp. 745–758, 2015.

[153] K. Okamura and K. Nohara, “Long-term arsenite exposure induces premature senescence in B cell lymphoma A20 cells,” Archives of Toxicology, vol. 90, no. 4, pp. 793–803, 2016.

[154] M. P. Murphy, “How mitochondria produce reactive oxygen species,” The Biochemical Journal, vol. 417, no. 1, pp. 1–13, 2009.

[155] F. Martinon, “Signaling by ROS drives inflammasome activation,” European Journal of Immunology, vol. 40, no. 3, pp. 616–619, 2010.

[156] R. N. Jadea, F. L. Powell, M. A. Jones et al., “Loss of NAMPT in aging retinal pigment epithelium reduces NAD<sup>+</sup> availability and promotes cellular senescence,” Aging, vol. 10, no. 6, pp. 1306–1323, 2018.

[157] A. J. Braakhuis, R. Nagulan, and V. Somerville, “The Effect of MitoQ on Aging-Related Biomarkers: A Systematic Review and Meta-Analysis,” Oxidative Medicine and Cellular Longevity, vol. 2018, Article ID 8575263, 12 pages, 2018.

[158] G. Saretzki, M. P. Murphy, and T. von Zglinicki, “MitoQ counteracts telomere shortening and elongates lifespan of...
Oxidative Medicine and Cellular Longevity

fibroblasts under mild oxidative stress,” Aging Cell, vol. 2, no. 2, pp. 141–143, 2003.

[159] J. F. Passos, G. Nelson, C. Wang et al., “Feedback between p21 and reactive oxygen production is necessary for cell senescence,” Molecular Systems Biology, vol. 6, no. 1, p. 347, 2010.

[160] A. Takahashi, N. Ohtani, K. Yamakoshi et al., “Mitogenic signalling and the p16INK4a-Rb pathway cooperate to enforce irreversible cellular senescence,” Nature Cell Biology, vol. 8, no. 11, pp. 1291–1297, 2006.

[161] T. A. Klimova, E. L. Bell, E. H. Shro et al., “Hyperoxia-induced premature senescence requires p53 and pRb, but not mitochondrial matrix ROS,” The FASEB Journal, vol. 23, no. 3, pp. 783–794, 2009.

[162] C. Correia-Melo and J. F. Passos, "Mitochondria: are they causal players in cellular senescence?" Biochimica et Biophysica Acta, vol. 1847, no. 11, pp. 1373–1379, 2015.

[163] Y. He, K. W. Leung, Y. Ren, J. Pei, J. Ge, and J. Tombran-Tink, “PEDF improves mitochondrial function in RPE cells during oxidative stress,” Investigative Ophthalmology & Visual Science, vol. 55, no. 10, pp. 6742–6755, 2014.

[164] E. E. Brown, A. J. DeWeerd, C. J. Idefonso, A. S. Lewin, and J. D. Ash, “Mitochondrial oxidative stress in the retinal pigment epithelium (RPE) led to metabolic dysfunction in both the RPE and retinal photoreceptors,” Redox Biology, vol. 24, p. 101201, 2019.

[165] X. Hu, M. A. Calton, S. Tang, and D. Vollrath, “Depletion of mitochondrial DNA in differentiated retinal pigment epithelial cells,” Scientific Reports, vol. 9, no. 1, p. 15355, 2019.

[166] C. Quijano, L. Cao, M. M. Fergusson et al., “Oncogene-induced senescence results in marked metabolic and bioenergetic alterations,” Cell Cycle, vol. 11, no. 7, pp. 1383–1392, 2012.

[167] J. Kaplon, L. Zheng, K. Meiss et al., “A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence,” Nature, vol. 498, no. 7452, pp. 109–112, 2013.

[168] P. Patil, M. Falabella, A. Saeed et al., “Oxidative stress-induced senescence markedly increases disc cell bioenergetics,” Mechanisms of Ageing and Development, vol. 180, pp. 97–106, 2019.

[169] J. R. Dörr, Y. Yu, M. Milanovic et al., “Synthetic lethal metabolic targeting of cellular senescence in cancer therapy,” Nature, vol. 501, no. 7467, pp. 421–425, 2013.

[170] F. Hariton, M. Xue, N. Rabbani, M. Fowler, and P. J. Thornalley, “Sulforaphane delays fibroblast senescence by curbing cellular glucose uptake, increased glycolysis, and oxidative damage,” Oxidative Medicine and Cellular Longevity, vol. 2018, Article ID 5642148, 16 pages, 2018.

[171] A. Delfarad, S. Parrish, J. A. Junge et al., “Inhibition of nucleotide synthesis promotes replicative senescence of human mammary epithelial cells,” The Journal of Biological Chemistry, vol. 294, no. 27, pp. 10564–10578, 2019.

[172] V. I. Korolchuk, S. Miwa, B. Carroll, and T. von Zglinicki, “Mitochondria in cell senescence: is mitophagy the weakest link?,” eBioMedicine, vol. 21, pp. 7–13, 2017.

[173] E. L. James, R. D. Michalek, G. N. Pitiyyage et al., “Senescent human fibroblasts show increased glycolysis and redox homeostasis with extracellular metabolomes that overlap with those of irreparable DNA damage, aging, and disease,” Journal of Proteome Research, vol. 14, no. 4, pp. 1854–1871, 2015.

[174] J. Martinez, D. Tarallo, L. Martinez-Palma et al., “Mitofusins modulate the increase in mitochondrial length, bioenergetics and secretory phenotype in therapy-induced senescent melanoma cells,” The Biochemical Journal, vol. 476, no. 17, pp. 2463–2486, 2019.

[175] T. Kamogashira, K. Hayashi, C. Fujimoto, S. Iwasaki, and T. Yasumasa, “Functionally and morphologically damaged mitochondria observed in auditory cells under senescence-inducing stress,” npj Aging and Mechanisms of Disease, vol. 3, no. 1, p. 2, 2017.

[176] D. W. Waters, K. E. C. Blokland, P. S. Pathinayake et al., “STAT3 regulates the onset of oxidant-induced senescence in lung fibroblasts,” American Journal of Respiratory Cell and Molecular Biology, vol. 61, no. 1, pp. 61–73, 2019.

[177] T. Nacarelli, A. Azar, and C. Sell, “Mitochondrial stress induces cellular senescence in an mTORC1-dependent manner,” Free Radical Biology & Medicine, vol. 95, pp. 133–154, 2016.

[178] M. Guha and N. G. Avadhani, “Mitochondrial retrograde signalling at the crossroads of tumor bioenergetics, genetics and epigenetics,” Mitochondrion, vol. 13, no. 6, pp. 577–591, 2013.

[179] S. M. Kwon, S. M. Hong, Y. K. Lee, S. Min, and G. Yoon, “Mitochondrial control of aging, metabolism and cell survival,” Biochemical Society Transactions, vol. 41, no. 1, pp. 111–117, 2013.

[180] M. Nam, T. E. Akie, M. Sanosaka et al., “Mitochondrial retrograde signalling connects respiratory capacity to thermogenic gene expression,” Scientific Reports, vol. 7, no. 1, p. 2013, 2017.

[181] N. S. Chandel, “Evolution of mitochondria as signaling organelles,” Cell Metabolism, vol. 22, no. 2, pp. 204–206, 2015.

[182] I. Bohovych and O. Khalmionschuk, “Sending out an SOS: mitochondria as a signaling hub,” Frontiers in Cell and Development Biology, vol. 4, p. 109, 2016.

[183] R. C. Scarpulla, “Nuclear control of respiratory chain expression by nuclear respiratory factors and PGC-1-related coactivator,” Annals of the New York Academy of Sciences, vol. 1147, no. 1, pp. 321–334, 2008.

[184] S. Chae, B. Y. Ahn, K. Byun et al., “A systems approach for decoding mitochondrial retrograde signaling pathways,” Science Signaling, vol. 6, no. 264, p. rs4, 2013.

[185] K. H. Kim, J. M. Son, B. A. Benayoun, and C. Lee, “The mitochondrial-encoded peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress,” Cell Metabolism, vol. 28, no. 3, pp. 516–524.e7, 2018.

[186] N. Sun, R. J. Youle, and T. Finkel, “The mitochondrial basis of aging,” Molecular Cell, vol. 61, no. 5, pp. 654–666, 2016.

[187] R. J. Youle and D. P. Narendra, “Mechanisms of mitophagy,” Nature Reviews Molecular Cell Biology, vol. 12, no. 1, pp. 9–14, 2011.

[188] L. Pernas and L. Scorrano, “Mito-morphosis: mitochondrial fusion, fission, and cristae remodeling as key mediators of cellular function,” Annual Review of Physiology, vol. 78, no. 1, pp. 505–531, 2016.
A. Olichon, L. J. Emorine, E. Descoins et al., "The human dynamin-related protein OPA1 is anchored to the mitochondrial inner membrane facing the inter-membrane space," *FEBS Letters*, vol. 523, no. 1-3, pp. 171–176, 2002.

P. G. Sreekumar, D. R. Hinton, J. Campisi, S. R. Sadda, and R. Kannan, "αβ crystallin chaperone peptide (mini Cry) inhibits senescence in RPE cells by modulating mitochondrial biogenesis and fusion proteins," *Investigative Ophthalmology & Visual Science*, vol. 60, p. 1950, 2019.

Y. Y. Park, S. Lee, M. Karbowski, A. Neutzner, R. J. Youle, and H. Cho, "Loss of MARCH5 mitochondrial E3 ubiquitin ligase induces cellular senescence through dynamin-related protein 1 and mitofusin 1," *Journal of Cell Science*, vol. 123, no. 4, pp. 619–626, 2010.

H. Hara, J. Araya, S. Ito et al., "Mitochondrial fragmentation in cigarette smoke-induced bronchial epithelial cell senescence," *American Journal of Physiology Lung Cellular and Molecular Physiology*, vol. 305, no. 10, pp. L737–L746, 2013.

C. Correia-Melo, F. D. Marques, R. Anderson et al., "Mitochondria are required for pro-ageing features of the senescent phenotype," *The EMBO Journal*, vol. 35, no. 7, pp. 724–742, 2016.

R. Summer, H. Shagbaghi, D. Schriner et al., "Activation of the mTORC1/PGC-1 axis promotes mitochondrial biogenesis and induces cellular senescence in the lung epithelium," *American Journal of Physiology Lung Cellular and Molecular Physiology*, vol. 316, no. 6, pp. L1049–L1060, 2019.

J. Zhu, K. Z. Q. Wang, and C. T. Chu, "After the banquet: mitochondrial biogenesis, mitophagy, and cell survival," *Autophagy*, vol. 9, no. 11, pp. 1663–1676, 2013.

K. Kaarniranta, J. Kajdanek, J. Morawiec, E. Pawlowska, and J. Blasiak, "PGC-1α protects RPE cells of the aging retina against oxidative stress-induced degeneration through the regulation of senescence and mitochondrial quality control. The significance for AMD pathogenesis," *International Journal of Molecular Sciences*, vol. 19, no. 8, p. 2317, 2018.

C. Kukat and N. G. Larsson, "mtDNA makes a U-turn for the mitochondrial nucleoid," *Trends in Cell Biology*, vol. 23, no. 9, pp. 457–463, 2013.

H. C. Lee, P. H. Yin, C. W. Chi, and Y. H. Wei, "Increase in mitochondrial mass in human fibroblasts under oxidative stress and during replicative cell senescence," *Journal of Biomedical Science*, vol. 9, no. 6, pp. 517–526, 2002.

P. V. S. Vasilieou, K. Evangelou, K. Vlasis et al., "Mitochondrial homeostasis and cellular senescence," *Cells*, vol. 8, no. 7, p. 686, 2019.

A. Egger, M. Samardzija, V. Sothilingam et al., "PGC-1α determines light damage susceptibility of the murine retina," *PLoS One*, vol. 7, no. 2, article e31272, 2012.

X. Zhang, S. Zhang, X. Liu et al., "Oxidation resistance 1 is a novel senolytic target," *Aging Cell*, vol. 17, no. 4, article e12780, 2018.

M. A. B. Rosales, D. Y. Shu, J. Jacobelli, and M. Saint-Geniez, "Loss of PGC-1α in RPE induces mesenchymal transition and promotes retinal degeneration," *Life Science Alliance*, vol. 2, no. 3, article e201800212, 2019.

S. Felszeghy, J. Viiri, J. J. Paterno et al., "Loss of NRF-2 and PGC-1 α genes leads to retinal pigment epithelium damage resembling dry age-related macular degeneration," *Redox Biology*, vol. 20, pp. 1–12, 2019.

N. E. Sharpless, N. Bardeesy, K. H. Lee et al., "Loss of p16INK4a with retention of p19Arf predisposes mice to tumorigenesis," *Nature*, vol. 413, no. 6851, pp. 86–91, 2001.

K. Ito, A. Hirao, F. Arai et al., "Reactive oxygen species act through p38 MAPK to limit the lifespan of hematopoietic stem cells," *Nature Medicine*, vol. 12, no. 4, pp. 446–451, 2006.

V. Janzen, R. Forkert, H. E. Fleming et al., "Stem-cell ageing modified by the cyclin-dependent kinase inhibitor p16INK4a," *Nature*, vol. 443, no. 7110, pp. 421–426, 2006.

J. W. Shay, "Role of telomeres and telomerase in aging and cancer," *Cancer Discovery*, vol. 6, no. 6, pp. 584–593, 2016.

J. L. Kirkland, T. Tchkonia, Y. Zhu, L. J. Niedernhofer, and P. D. Robbins, "The clinical potential of senolytic drugs," *Journal of the American Geriatrics Society*, vol. 65, no. 10, pp. 2297–2301, 2017.

M. E. Waaijer, W. E. Parish, B. H. Strongitharm et al., "The number of p16INK4a positive cells in human skin reflects biological age," *Aging Cell*, vol. 11, no. 4, pp. 722–725, 2012.

Y. Zhu, T. Tchkonia, T. Pirtskhalava et al., "The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs," *Aging Cell*, vol. 14, no. 4, pp. 644–658, 2015.

Y. Sun, J. P. Coppé, and E. W. F. Lam, "Cellular senescence: the sought or the unwanted?" Trends in Molecular Medicine, vol. 24, no. 10, pp. 871–885, 2018.

S. N. Knoppert, F. A. Valentijn, T. Q. Nguyen, R. Goldschmeding, and L. L. Falke, "Cellular senescence and the kidney: potential therapeutic targets and tools," *Frontiers in Pharmacology*, vol. 10, p. 770, 2019.

C. Tse, A. R. Shoemaker, J. Adickes et al., "ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor," *Cancer Research*, vol. 68, no. 9, pp. 3421–3428, 2008.

J. Chang, Y. Wang, L. Shao et al., "Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice," *Nature Medicine*, vol. 22, no. 1, pp. 78–83, 2016.

Y. Zhu, T. Tchkonia, H. Fuhrmann-Stroissnigg et al., "Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors," *Aging Cell*, vol. 15, no. 3, pp. 428–435, 2016.

T. J. Bussian, A. Aziz, C. F. Meyer, B. L. Swenson, J. M. van Deursen, and D. J. Baker, "Clearance of senescent glial cells prevents tau-dependent pathology and cognitive decline," *Nature*, vol. 562, no. 7728, pp. 578–582, 2018.

B. G. Childs, D. J. Baker, T. Wijsnake, C. A. Conover, J. Campisi, and J. M. van Deursen, "Senescent intimal foam cells are deleterious at all stages of atherosclerosis," *Science*, vol. 354, no. 6311, pp. 472–477, 2016.
reverses persistent pulmonary fibrosis induced by ionizing radiation in mice,” *International Journal of Radiation Oncology, Biology, Physics*, vol. 99, no. 2, pp. 353–361, 2017.

[223] Y. Zhu, E. J. Doornebal, T. Pirtskhalava et al., “New agents that target senescent cells: the flavone, fisetin, and the BCL-X<sub>L</sub> inhibitors, A1331852 and A1155463,” *Aging*, vol. 9, no. 3, pp. 955–963, 2017.

[224] M. J. Yousefzadeh, Y. Zhu, S. J. McGowan et al., “Fisetin is a senotherapeutic that extends health and lifespan,” *eBioMedicine*, vol. 36, pp. 18–28, 2018.

[225] H. Fuhrmann-Stroissnigg, Y. Y. Ling, J. Zhao et al., “Identification of HSP90 inhibitors as a novel class of senolytics,” *Nature Communications*, vol. 8, no. 1, p. 422, 2017.

[226] O. H. Jeon, C. Kim, R. M. Laberge et al., “Local clearance of senescent cells attenuates the development of post-traumatic osteoarthritis and creates a pro-regenerative environment,” *Nature Medicine*, vol. 23, no. 6, pp. 775–781, 2017.

[227] J. Campisi, P. Kapahi, G. J. Lithgow, S. Melow, J. C. Newman, and E. Verdin, “From discoveries in ageing research to therapeutics for healthy ageing,” *Nature*, vol. 571, no. 7764, pp. 183–192, 2019.

[228] H. Yang, H. Wang, J. Ren, Q. Chen, and Z. J. Chen, “cGAS is essential for cellular senescence,” *Proceedings of the National Academy of Sciences*, vol. 114, no. 23, pp. E4612–E4620, 2017.

[229] Y. Wu, Q. Wei, and J. Yu, “The cGAS/STING pathway: a sensor of senescence-associated DNA damage and trigger of inflammation in early age-related macular degeneration,” *Clinical Interventions in Aging*, vol. Volume 14, pp. 1277–1283, 2019.

[230] L. J. Hickson, L. P. LGP, S. A. Bobart et al., “Senolytics decrease senescent cells in humans: preliminary report from a clinical trial of dasatinib plus quercetin in individuals with diabetic kidney disease,” *eBioMedicine*, vol. 47, pp. 446–456, 2019.

[231] J. N. Justice, A. M. Nambiar, T. Tchkonia et al., “Senolytics in idiopathic pulmonary fibrosis: results from a first-in-human, open-label, pilot study,” *eBioMedicine*, vol. 40, pp. 554–563, 2019.

[232] J. M. van Deursen, “Senolytic therapies for healthy longevity,” *Science*, vol. 364, no. 6441, pp. 636–637, 2019.

[233] A. Hernandez-Segura, T. V. de Jong, S. Melow, V. Guryev, J. Campisi, and M. Demaria, “Unmasking transcriptional heterogeneity in senescent cells,” *Current Biology*, vol. 27, no. 17, pp. 2652–2660.e4, 2017.

[234] J. L. Kirkland and T. Tchkonia, “Cellular senescence: a translational perspective,” *eBioMedicine*, vol. 21, pp. 21–28, 2017.